Repligen corp stock.

Summary. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. Repligen Corporation to Present at Upcoming Investor Conferences. Nov. 07. AQ. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.CI. Transcript : Repligen Corporation Presents at The Stifel 2023 Annual Healthcare Conference, Nov-15-2023 08:00 AM. Nov. 15. CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07.Oct 30, 2023 · Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%. Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.Dec 2, 2023 · With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997 . If you had invested in Repligen stock at $0.78 , your return over the last 25 years would have been 21,019.08% , for an annualized return of 23.88% (not ...

305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making an Impact ”, the report highlights …

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common …View Repligen Corporation RGEN investment & stock information. Get the latest Repligen Corporation RGEN detailed stock quotes, stock data, Real-Time ECN, ...Get Repligen Corp (RGEN.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... Repligen Corp RGEN.OQ. Official Data Partner ...Dimensional Fund Advisors LP raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 8.2% during the 2nd quarter, HoldingsChannel.com …

America’s largest Marine Corps bases include North Carolina’s Marine Corps Base Camp Lejeune, and California’s Marine Corps Air Ground Combat Center Twentynine Palms and Marine Corps Base Camp Pendleton.

Nov 3, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 12.34% in the past year. Currently, Repligen Corp’s price-earnings ratio is 74.0. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, …Find real-time RGEN - Repligen Corp stock quotes, company profile, news and forecasts from CNN Business. Repligen Corp stock has a Momentum Score of 57, Estimate Revisions Score of 50 and Quality Score of 73. Comparing DexCom, Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Item 1.01 Entry into a Material Definitive Agreement. On March 4, 2022, Repligen Corporation (the "Company") entered into the Second Supplemental Indenture (the "Second Supplemental Indenture") to the Base Indenture, dated July 19, 2019, as supplemented by that certain First Supplemental Indenture thereto, dated July 19, 2019 …Repligen Corp’s ( RGEN) price is currently up 0.21% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $171.57. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.02%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 81.2. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.See Insiders’ Hot Stocks on TipRanks >> Based on Repligen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $182.66 million and a net ...Dimensional Fund Advisors LP raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 8.2% during the 2nd quarter, HoldingsChannel.com …Find the latest Repligen Corp (RGN.MU) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist...

Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.Get real-time Repligen (RGEN) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing.

Waltham, Massachusetts 02453. Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $801.54M. Net Income $185.96M. 2022 Sales Growth 19.54%.The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ...Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 41. Comparing Premier Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36.The stock’s market cap achieved a total value of $6.67 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Repligen Corp. (NASDAQ:RGEN) is 49.48.305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Dec 1, 2023 · See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Repligen Corporation stock price live 159.46, this page displays NASDAQ RGEN stock exchange data. View the RGEN premarket stock price ahead of the market session or …Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.

Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Get market updates, educational videos, webinars, and stock analysis. Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.

On average, Wall Street analysts predict. that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a potential upside of 25.33% from the current RGEN share price of $150.60.

When starting a business, one of the most important decisions you’ll have to make is choosing the right legal structure. Limited Liability Companies (LLCs) and S Corporations (S Corps) are two popular options that offer liability protection...Repligen Corp (RGEN) Stock Shows Promising Performance on September 12, 2023: Analysts Predict 22.75% Increase. On September 12, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN have a median …During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $157.11. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 36.92%.Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.On average, Wall Street analysts predict that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Oct 12, 2021. The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop ...Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for ...WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making an Impact ”, the report highlights …

Oct 9, 2023 · With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ... Information on stock, financials, earnings, subsidiaries, investors, and executives for Repligen. Use the PitchBook Platform to explore the full profile. ... Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies an. Biotechnology. Waltham, MA. 2,025 As of 2022 00000000. 000000.Allworth Financial LP raised its holdings in Repligen by 62.7% in Q4 and now owns 262 shares of the biotechnology company’s stock valued at $44,000 after adding another 101 shares to its portfolio. Moreover, Achmea Investment Management B.V. entered into a new position with Repligen in the fourth quarter worth $49,000.Repligen Corporation Stock price Equities RGEN US7599161095 Medical Equipment, Supplies & Distribution Summary Quotes Charts News Ratings Calendar …Instagram:https://instagram. half dollar coin pricesabnfxenergy source minerals stock symboltesla rating With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 48.1. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%. us quarters valuelifemd stock During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $157.11. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 36.92%. einsteingpt salesforce The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...On November 1, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN had a median target of $190.00, with a high estimate of $210.00 and a low estimate of $148.00. This median estimate represents a significant increase of …Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...